Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1121–1125. doi: 10.1128/aac.40.5.1121

In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis.

E M Narcisi 1, W E Secor 1
PMCID: PMC163276  PMID: 8723451

Abstract

Trichomonas vaginalis is a common sexually transmitted protozoan parasite. Although often considered simply a nuisance infection, T. vaginalis has been implicated in premature rupture of placental membranes and increases in the risk of acquiring human immunodeficiency virus. Metronidazole, a 5-nitroimidazole, is currently the drug of choice to treat T. vaginalis infection. Because some patients have severe reactions to metronidazole and others are infected with metronidazole-resistant T. vaginalis, we were prompted to investigate alternative therapies. Tinidazole, another 5-nitroimidazole used in other countries to treat T. vaginalis infections, and furazolidone, a nitrofuran presently used to treat giardiasis and infections with some anaerobic enteric bacteria, were investigated for effectiveness against 9 metronidazole-susceptible and 12 metronidazole-resistant T. vaginalis patient isolates. The in vitro aerobic and anaerobic minimum lethal concentrations (MLC) and the time for drug efficacy were determined. Tinidazole killed the metronidazole-susceptible isolates at a low MLC but was effective against only 4 of the 12 metronidazole-resistant isolates. In contrast, furazolidone was effective at a low MLC for all isolates. When tinidazole was effective, it required > 6 h to kill trichomonads. However, furazolidone killed both metronidazole-susceptible and resistant trichomonads within 2 to 3 h of exposure. These data suggest that furazolidone may be a good candidate for treating metronidazole-resistant trichomoniasis and that further investigation of this drug is warranted.

Full Text

The Full Text of this article is available as a PDF (262.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Artem'ev S. A., Potapnev F. P., Voskresenskaia G. A. Furazolidon v terapii trikhomoniaza u muzhchin. Sov Med. 1966 Oct;29(10):128–130. [PubMed] [Google Scholar]
  2. Cates W., Jr, Joesoef M. R., Goldman M. B. Atypical pelvic inflammatory disease: can we identify clinical predictors? Am J Obstet Gynecol. 1993 Aug;169(2 Pt 1):341–346. doi: 10.1016/0002-9378(93)90085-w. [DOI] [PubMed] [Google Scholar]
  3. DIAMOND L. S. The establishment of various trichomonads of animals and man in axenic cultures. J Parasitol. 1957 Aug;43(4):488–490. [PubMed] [Google Scholar]
  4. Dombrowski M. P., Sokol R. J., Brown W. J., Bronsteen R. A. Intravenous therapy of metronidazole-resistant Trichomonas vaginalis. Obstet Gynecol. 1987 Mar;69(3 Pt 2):524–525. [PubMed] [Google Scholar]
  5. Forsgren A., Forssman L. Metronidazole-resistant Trichomonas vaginalis. Br J Vener Dis. 1979 Oct;55(5):351–353. doi: 10.1136/sti.55.5.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fowler K. B., Pass R. F. Sexually transmitted diseases in mothers of neonates with congenital cytomegalovirus infection. J Infect Dis. 1991 Aug;164(2):259–264. doi: 10.1093/infdis/164.2.259. [DOI] [PubMed] [Google Scholar]
  7. Gram I. T., Macaluso M., Churchill J., Stalsberg H. Trichomonas vaginalis (TV) and human papillomavirus (HPV) infection and the incidence of cervical intraepithelial neoplasia (CIN) grade III. Cancer Causes Control. 1992 May;3(3):231–236. doi: 10.1007/BF00124256. [DOI] [PubMed] [Google Scholar]
  8. Grodstein F., Goldman M. B., Cramer D. W. Relation of tubal infertility to history of sexually transmitted diseases. Am J Epidemiol. 1993 Mar 1;137(5):577–584. doi: 10.1093/oxfordjournals.aje.a116711. [DOI] [PubMed] [Google Scholar]
  9. Grossman J. H., 3rd, Galask R. P. Persistent vaginitis caused by metronidazole-resistant trichomonas. Obstet Gynecol. 1990 Sep;76(3 Pt 2):521–522. [PubMed] [Google Scholar]
  10. Hamed K. A., Studemeister A. E. Successful response of metronidazole-resistant trichomonal vaginitis to tinidazole. A case report. Sex Transm Dis. 1992 Nov-Dec;19(6):339–340. [PubMed] [Google Scholar]
  11. Heine P., McGregor J. A. Trichomonas vaginalis: a reemerging pathogen. Clin Obstet Gynecol. 1993 Mar;36(1):137–144. doi: 10.1097/00003081-199303000-00019. [DOI] [PubMed] [Google Scholar]
  12. Heyworth R., Simpson D., McNeillage G. J., Robertson D. H., Young H. Isolation of Trichomonas vaginalis resistant to metronidazole. Lancet. 1980 Aug 30;2(8192):476–478. doi: 10.1016/s0140-6736(80)91911-x. [DOI] [PubMed] [Google Scholar]
  13. Johnson P. J. Metronidazole and drug resistance. Parasitol Today. 1993 May;9(5):183–186. doi: 10.1016/0169-4758(93)90143-4. [DOI] [PubMed] [Google Scholar]
  14. Kanwar A. J., Sharma R., Rajagopalan M., Kaur S. Fixed drug eruption due to tinidazole with cross-reactivity with metronidazole. Dermatologica. 1990;180(4):277–277. doi: 10.1159/000248048. [DOI] [PubMed] [Google Scholar]
  15. Kharsany A. B., Hoosen A. A., Moodley J., Bagaratee J., Gouws E. The association between sexually transmitted pathogens and cervical intra-epithelial neoplasia in a developing community. Genitourin Med. 1993 Oct;69(5):357–360. doi: 10.1136/sti.69.5.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kulda J., Vojtechovská M., Tachezy J., Demes P., Kunzová E. Metronidazole resistance of Trichomonas vaginalis as a cause of treatment failure in trichomoniasis--A case report. Br J Vener Dis. 1982 Dec;58(6):394–399. doi: 10.1136/sti.58.6.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Laga M., Manoka A., Kivuvu M., Malele B., Tuliza M., Nzila N., Goeman J., Behets F., Batter V., Alary M. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS. 1993 Jan;7(1):95–102. doi: 10.1097/00002030-199301000-00015. [DOI] [PubMed] [Google Scholar]
  18. Lindmark D. G., Müller M. Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles. Antimicrob Agents Chemother. 1976 Sep;10(3):476–482. doi: 10.1128/aac.10.3.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lossick J. G., Müller M., Gorrell T. E. In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis. 1986 May;153(5):948–955. doi: 10.1093/infdis/153.5.948. [DOI] [PubMed] [Google Scholar]
  20. McFadzean J. A., Pugh I. M., Squires S. L., Whelan J. P. Further observations on strain sensitivity of Trichomonas vaginalis to metronidazole. Br J Vener Dis. 1969 Jun;45(2):161–162. doi: 10.1136/sti.45.2.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Meingassner J. G., Mieth H. Cross-resistance of Trichomonads to 5-nitroimidazole-derivatives. Experientia. 1976 Feb 15;32(2):183–184. doi: 10.1007/BF01937754. [DOI] [PubMed] [Google Scholar]
  22. Meingassner J. G., Thurner J. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother. 1979 Feb;15(2):254–257. doi: 10.1128/aac.15.2.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Minkoff H., Grunebaum A. N., Schwarz R. H., Feldman J., Cummings M., Crombleholme W., Clark L., Pringle G., McCormack W. M. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol. 1984 Dec 15;150(8):965–972. doi: 10.1016/0002-9378(84)90392-2. [DOI] [PubMed] [Google Scholar]
  24. Mishra D., Mobashir M., Zaheer M. S. Fixed drug eruption and cross-reactivity between tinidazole and metronidazole. Int J Dermatol. 1990 Dec;29(10):740–740. doi: 10.1111/j.1365-4362.1990.tb03788.x. [DOI] [PubMed] [Google Scholar]
  25. Moreno S. N., Mason R. P., Muniz R. P., Cruz F. S., Docampo R. Generation of free radicals from metronidazole and other nitroimidazoles by Tritrichomonas foetus. J Biol Chem. 1983 Apr 10;258(7):4051–4054. [PubMed] [Google Scholar]
  26. Müller M., Gorrell T. E. Metabolism and metronidazole uptake in Trichomonas vaginalis isolates with different metronidazole susceptibilities. Antimicrob Agents Chemother. 1983 Nov;24(5):667–673. doi: 10.1128/aac.24.5.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Müller M., Lossick J. G., Gorrell T. E. In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis. Sex Transm Dis. 1988 Jan-Mar;15(1):17–24. doi: 10.1097/00007435-198801000-00004. [DOI] [PubMed] [Google Scholar]
  28. Müller M., Meingassner J. G., Miller W. A., Ledger W. J. Three metronidazole-resistant strains of Trichomonas vaginalis from the United States. Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 1):808–812. doi: 10.1016/s0002-9378(16)32741-7. [DOI] [PubMed] [Google Scholar]
  29. Nyirjesy P., Weitz M. V., Gelone S. P., Fekete T. Paromomycin for nitroimidazole-resistant trichomonosis. Lancet. 1995 Oct 21;346(8982):1110–1110. doi: 10.1016/s0140-6736(95)91788-8. [DOI] [PubMed] [Google Scholar]
  30. Robertson D. H., Heyworth R., Harrison C., Lumsden W. H. Treatment failure in Trichomonas vaginalis infections in females. I. Concentrations of metronidazole in plasma and vaginal content during normal and high dosage. J Antimicrob Chemother. 1988 Mar;21(3):373–378. doi: 10.1093/jac/21.3.373. [DOI] [PubMed] [Google Scholar]
  31. Robinson S. C. Trichomonal Vaginitis Resistant to Metranidazole. Can Med Assoc J. 1962 Apr 7;86(14):665–665. [PMC free article] [PubMed] [Google Scholar]
  32. SCHWARTZ J. Tricofuron therapy of Trichomonas vaginitis. Obstet Gynecol. 1956 Mar;7(3):312–314. [PubMed] [Google Scholar]
  33. Sears S. D., O'Hare J. In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents. Antimicrob Agents Chemother. 1988 Jan;32(1):144–146. doi: 10.1128/aac.32.1.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Soper D. E., Bump R. C., Hurt W. G. Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. Am J Obstet Gynecol. 1990 Sep;163(3):1016–1023. doi: 10.1016/0002-9378(90)91115-s. [DOI] [PubMed] [Google Scholar]
  35. Spitzbart H., Wilk I. Ist Paromomycin zur Behandlung der Trichomonadeninfektion bei der Frau geeignet? II. Klinische Erfahrungen. Zentralbl Gynakol. 1966 Apr 30;88(18):563–566. [PubMed] [Google Scholar]
  36. Stern I. J., Hollifield R. D., Wilk S., Buzard J. A. The anti-monoamine oxidase effects of furazolidone. J Pharmacol Exp Ther. 1967 Jun;156(3):492–499. [PubMed] [Google Scholar]
  37. Tocher J. H., Edwards D. I. Evidence for the direct interaction of reduced metronidazole derivatives with DNA bases. Biochem Pharmacol. 1994 Sep 15;48(6):1089–1094. doi: 10.1016/0006-2952(94)90144-9. [DOI] [PubMed] [Google Scholar]
  38. Voolmann T., Boreham P. Metronidazole resistant Trichomonas vaginalis in Brisbane. Med J Aust. 1993 Oct 4;159(7):490–490. doi: 10.5694/j.1326-5377.1993.tb137978.x. [DOI] [PubMed] [Google Scholar]
  39. White A. H. Absorption, distribution, metabolism, and excretion of furazolidone. A review of the literature. Scand J Gastroenterol Suppl. 1989;169:4–10. doi: 10.3109/00365528909091325. [DOI] [PubMed] [Google Scholar]
  40. Willmott F., Say J., Downey D., Hookham A. Zinc and recalcitrant trichomoniasis. Lancet. 1983 May 7;1(8332):1053–1053. doi: 10.1016/s0140-6736(83)92684-3. [DOI] [PubMed] [Google Scholar]
  41. Wong C. A., Wilson P. D., Chew T. A. Povidone-iodine in the treatment of metronidazole-resistant trichomonas vaginalis. Aust N Z J Obstet Gynaecol. 1990 May;30(2):169–171. doi: 10.1111/j.1479-828x.1990.tb03255.x. [DOI] [PubMed] [Google Scholar]
  42. Zhang Z. F., Begg C. B. Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol. 1994 Aug;23(4):682–690. doi: 10.1093/ije/23.4.682. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES